All manuscripts
Publications CAR T Cells

Preparation of cryopreserved chimeric antigen receptor T cells for the locoreogional delivery to the neural axis

Published Journal Cytotherapy

Share
No image preview

Overview

Describes a thaw/wash method for CAR-T cells for intracranial delivery. B7-H3-CAR T cells were generated and expanded in G-Rex® culture devices using X-VIVO 15 media with cytokines.

What this paper found

A simple thaw/wash procedure removed nearly all DMSO from cryopreserved B7-H3-CAR T cell products while keeping them viable, sterile and functional for intracranial delivery to children with brain tumors. Thawed cells were equilibrated for 5 minutes with one volume of preservative-free normal saline, diluted with eight further volumes, washed by centrifugation and concentrated to a dose of 30 × 10^6 cells in 2 mL. Calculated DMSO fell from 5% to 0.0125–0.025%. In three validation products, final viability averaged 85.3% and viable cell recovery 76.5% of pre-cryopreservation values, endotoxin stayed at or below 0.05 EU/mL and sterility cultures were negative. Three hours after thaw, mean viability was 80.0%, and CAR/41BBL co-expression and killing of B7-H3-positive THP-1 cells matched unwashed controls.

Note: The procedure is manual and multistep; the authors note it may not be ideal for later-phase clinical studies or FDA-approved CAR T cell products and that the process needs further optimization.

Although the DMSO safety limit for IC infusion is not known, this method successfully reduced DMSO% as calculated to less than 0.025% below the internally set limit of 0.5%. — Salem Akel, Leigh Poston, Jeoungeun J. Park, Susan B. Schoultz, Lina Alloush, Fei Zheng, Sheng Zhou, Timothy Lockey, Catherine Willis, Christopher DeRenzo, Stephen Gottschalk, Cytotherapy

Study details

Authors
Salem Akel, Leigh Poston, Jeoungeun J. Park, Susan B. Schoultz, Lina Alloush, Fei Zheng, Sheng Zhou, Timothy Lockey, Catherine Willis, Christopher DeRenzo, Stephen Gottschalk
Institution
Human Applications Laboratory, St. Jude Children’s Research Hospital, Memphis, TN, United States · Experimental Cellular Therapeutic Laboratory, St. Jude Children’s Research Hospital, Memphis, TN, United States · Therapeutics Production and Quality, St. Jude Children’s Research Hospital, Memphis, TN, United States · Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN, United States
Journal
Cytotherapy
Year
2023
PMID / PMC
PMID: 37676217 · PMC
Cell type(s)
CAR T Cells
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

After transduction with a B7-H3-CAR lentiviral vector, the T cells were seeded and expanded in G-Rex® culture devices (Wilson Wolf) in X-VIVO 15 with 5% human AB serum and 10 ng/mL IL-7 and IL-15. Cytokines were replenished after 3 to 4 days, and the CAR T cells were harvested on day 7 or 8 and cryopreserved in freezing medium containing 5% DMSO. These cGMP-manufactured products were the starting material for the thaw/wash procedure.

Explore related

Full citation

Akel S, Poston L, Park JJ, et al. Preparation of cryopreserved chimeric antigen receptor T cells for the locoreogional delivery to the neural axis. Cytotherapy. 2023;25(11):1149-1154.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →